Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Harte Hanks (HHS) Eyes Potential +25% Move to $5.00 Star Equity (STRR) Merger Price

Harte Hanks (HHS) Eyes Potential +25% Move to $5.00 Star Equity (STRR) Merger Price

Key Takeaways

  • The central target discussed here is $5.00 per share — the per-share consideration under the definitive merger agreement between Harte Hanks, Inc. (HHS) and Star Equity Holdings (STRR).
  • This target is not an analyst-derived price target; with effectively no current sell-side coverage, it comes from public market discussion and the documented terms of a board-approved transaction.
  • At a recent price near $4.01, reaching $5.00 implies roughly 25% upside — a substantial move that mainly reflects the gap between the current price and the agreed deal value.
  • No credible, current analyst price targets exist; older, stale targets in the $12–$17.50 range predate the merger and are not usable for a forward-looking estimate.
  • The strongest supporting factor is the board-recommended acquisition, whose go-shop period expired without a superior proposal; closing is targeted before year-end 2026.
  • The biggest risks are deal-completion uncertainty — shareholder approval, financing, and the Form S-4 registration — plus the fact that half the consideration is paid in preferred stock, not cash.
  • For more context on this ticker, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
  • You can also explore Trending AI Robots to see automated strategies monitoring stocks and ETFs like this one.

How the $5.00 Target Came About

Because Harte Hanks carries effectively no active analyst coverage — TipRanks lists zero covering analysts and no forward price target, while figures still circulating on aggregator sites reflect stale, pre-merger research — the standard "average analyst price target" method does not apply here. Instead, the most realistic and widely discussed price objective is the $5.00 per share merger consideration set out in the definitive agreement announced on August 14, 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Under those terms, Star Equity agreed to acquire Harte Hanks at a value of $5.00 per share, or roughly $38.4 million in equity value, with stockholders able to elect up to 50% cash (capped near $19.2 million) and the balance in Star's 10% Series A Cumulative Perpetual Preferred Stock (STRRP) at 0.50 preferred shares per Harte Hanks share. This is a documented, verifiable transaction price rather than a sell-side forecast.

Where the Stock Stands Today and the Road to $5.00

Harte Hanks, Inc. is a global customer experience and business process outsourcing company operating through its Revenue Solutions, Customer Care, and Fulfillment and Logistics segments. The stock has recently traded near $4.01, with a 52-week range of roughly $2.00 to $4.67. A move to $5.00 therefore requires an advance of approximately 25%, a substantial gap that exists largely because the market is discounting for the possibility that the merger does not close on current terms.

The path to $5.00 is unusual for a stock price target: it is less about operating fundamentals and more about merger arbitrage. If the transaction closes as agreed, holders would receive consideration structured around the $5.00 valuation. If it does not, the share price would likely revert toward standalone fundamentals, which have been challenged — revenue has declined and the company has reported losses.

Factors That Could Push the Stock Higher

  • The Harte Hanks board unanimously approved the deal and has reaffirmed its recommendation of the Star merger.
  • The 30-day go-shop period expired in September 2026 after soliciting 93 parties; the board did not identify a superior proposal, and no alternative transaction has been announced.
  • Research firm Sidoti noted the proposed merger was "likely to close" on the agreed terms, citing the board's view that the Star offer was superior to other bids received.
  • Star has outlined about $10 million in estimated annual cost synergies and financing plans combining cash on hand, the preferred stock, and Harte Hanks' $25 million credit facility.

Risks That Might Keep Shares Below Target

  • The merger still requires approval by Harte Hanks stockholders and the effectiveness of a Form S-4 registration statement, among other closing conditions.
  • Half the consideration is Star preferred stock, whose market value can fluctuate, meaning the effective value of the deal may differ from a simple $5.00 cash figure.
  • The existing gap between the share price and $5.00 itself signals investor skepticism about timing or completion.
  • Standalone fundamentals are weak: revenue contracted roughly 14% in 2025, and the company has reported net losses and negative free cash flow, which would weigh on the stock if the deal were to fail.

Key Technical Levels to Watch

The most meaningful level is the $5.00 merger price itself, which acts as a natural ceiling for the stock while the deal is pending — shares rarely trade meaningfully above an agreed cash-and-stock takeover price absent a competing bid. Below that, the recent 52-week high near $4.67 is a notable reference point, and the stock has generally held above the $3.90–$4.00 area in recent sessions. These levels matter less as classic support or resistance and more as a gauge of how the market is pricing deal-completion risk.

Timeline and Key Events to Follow

Unlike a conventional analyst price target, which usually reflects a roughly 12-month research horizon, the $5.00 objective here is tied to a specific event: the merger, which both companies have said they expect to close before the end of 2026. Investors should watch for the Harte Hanks special stockholder meeting and vote, the effectiveness of the Form S-4, any changes in financing or deal terms, and any competing or superior proposals that could emerge. The company's quarterly results, including the most recent third-quarter report, remain relevant mainly as a fallback measure of standalone value. I'm watching this closely as the timeline tightens.

My Final Take

The question of whether Harte Hanks can reach $5.00 is really a question about whether the pending Star Equity acquisition closes on its agreed terms. The $5.00 figure is a transaction price, not an analyst consensus, and it sits roughly 25% above the recent trading level — a substantial gap that reflects genuine completion risk rather than fundamental upside. The strongest supports are the board's recommendation and the failure of the go-shop process to surface a superior bid, while the principal obstacles are the outstanding stockholder vote, financing conditions, and the preferred-stock component of the consideration. Investors should monitor the special meeting, regulatory filings, and any changes to deal terms, while recognizing that if the merger were to fail, the stock would likely be reassessed on much weaker standalone fundamentals. No outcome is guaranteed.

Exploring AI Daily Buy/Sell Signals for Merger Situations

In my own research process, I rely on Tickeron's AI Daily Buy/Sell Signals to help track momentum shifts in deals like this one. The tool uses artificial intelligence to monitor thousands of stocks and generate signals based on technical behavior and market conditions. It has been useful for spotting changes in sentiment when traditional coverage is limited, allowing me to stay informed on positions without constant manual review.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HHS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HHS in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 20, 2026

HHS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 39 cases where HHS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HHS's RSI Oscillator exited the oversold zone, 19 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.

The Moving Average Convergence Divergence (MACD) for HHS just turned positive on November 09, 2026. Looking at past instances where HHS's MACD turned positive, the stock continued to rise in 41 of 52 cases over the following month. The odds of a continued upward trend are 79%.

Following a +2.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where HHS advanced for three days, in 181 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 52 cases where HHS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HHS as a result. In 74 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

HHS moved below its 50-day moving average on October 20, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HHS crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HHS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

The Aroon Indicator for HHS entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.923) is normal, around the industry mean (-1.578). P/E Ratio (-5.143) is within average values for comparable stocks, (18.965). Projected Growth (PEG Ratio) (0.472) is also within normal values, averaging (0.772). Dividend Yield (0.859) settles around the average of (674.816) among similar stocks. P/S Ratio (0.219) is also within normal values, averaging (2.059).

The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. HHS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HHS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are 3M Company (NYSE:MMM), Honeywell International (NASDAQ:HON).

Industry description

Industrial Conglomerates specialize in numerous types of products, most of which comprise industrial goods, while some also go towards meeting household needs. Honeywell (makes engineering services and aerospace systems), United Technologies Corporation(manufactures aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building systems, and industrial products, among others), 3M (over 60,000 products under several world-renowned brands, including adhesives, abrasives, laminates, passive fire protection, personal protective equipment, window films, paint protection films, dental and orthodontic products, electrical & electronic connecting and insulating materials, medical products, car-care products, electronic circuits, healthcare software and optical films).

Market Cap

The average market capitalization across the Industrial Conglomerates Industry is 7.16B. The market cap for tickers in the group ranges from 62.16K to 156.47B. HTHIF holds the highest valuation in this group at 156.47B. The lowest valued company is FSTF at 62.16K.

High and low price notable news

The average weekly price growth across all stocks in the Industrial Conglomerates Industry was -5%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was -14%. GHC experienced the highest price growth at 6%, while NXAT experienced the biggest fall at -27%.

Volume

The average weekly volume growth across all stocks in the Industrial Conglomerates Industry was -82%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was 59%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 39
P/E Growth Rating: 63
Price Growth Rating: 58
SMR Rating: 75
Profit Risk Rating: 83
Seasonality Score: -6 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of marketing and shopper advertising services

Industry IndustrialConglomerates

Industry
Advertising Or Marketing Services
Address
1 Executive Drive
Phone
+1 512 434-1100
Employees
2109
Web
https://www.hartehanks.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.